Trial · NCT02593773
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 20
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Discontinuations Due to AEs | Interferon γ-1b | ≥ 1 TEAE | 78 | participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Discontinuations Due to AEs | Interferon γ-1b | ≥ 1 Related TEAE | 61 | participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Discontinuations Due to AEs | Interferon γ-1b | ≥ 1 SAE | 4 | participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Discontinuations Due to AEs | Interferon γ-1b | ≥ 1 Related SAE | 0 | participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Discontinuations Due to AEs | Interferon γ-1b | ≥ 1 TEAE Leading to Discontinuation | 1 | participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Discontinuations Due to AEs | Interferon γ-1b | ≥ 1 TEAE Leading to Death | 1 | participants | |
| Number of Participants With Positive/Negative Neutralizing Antibody (NAb) and Anti-Drug Antibody (ADA) Tests | Interferon γ-1b | Baseline ADA = negative | 85 | participants | |
| Number of Participants With Positive/Negative Neutralizing Antibody (NAb) and Anti-Drug Antibody (ADA) Tests | Interferon γ-1b | Baseline ADA = positive | 1 | participants | |
| Number of Participants With Positive/Negative Neutralizing Antibody (NAb) and Anti-Drug Antibody (ADA) Tests | Interferon γ-1b | Baseline NAb = negative | 1 | participants | |
| Number of Participants With Positive/Negative Neutralizing Antibody (NAb) and Anti-Drug Antibody (ADA) Tests | Interferon γ-1b | Baseline NAb = positive | 0 | participants | |
| Number of Participants With Positive/Negative Neutralizing Antibody (NAb) and Anti-Drug Antibody (ADA) Tests | Interferon γ-1b | Week 4 ADA = negative | 84 | participants | |
| Number of Participants With Positive/Negative Neutralizing Antibody (NAb) and Anti-Drug Antibody (ADA) Tests | Interferon γ-1b | Week 4 ADA = positive | 0 | participants | |
| Number of Participants With Positive/Negative Neutralizing Antibody (NAb) and Anti-Drug Antibody (ADA) Tests | Interferon γ-1b | Week 13 ADA = negative | 79 | participants | |
| Number of Participants With Positive/Negative Neutralizing Antibody (NAb) and Anti-Drug Antibody (ADA) Tests | Interferon γ-1b | Week 13 ADA = positive | 0 | participants | |
| Number of Participants With Positive/Negative Neutralizing Antibody (NAb) and Anti-Drug Antibody (ADA) Tests | Interferon γ-1b | Week 26 ADA = negative | 64 | participants | |
| Number of Participants With Positive/Negative Neutralizing Antibody (NAb) and Anti-Drug Antibody (ADA) Tests | Interferon γ-1b | Week 26 ADA = positive | 0 | participants | |
| Number of Participants With Positive/Negative Neutralizing Antibody (NAb) and Anti-Drug Antibody (ADA) Tests | Interferon γ-1b | Week 28 (Follow-up) ADA = negative | 56 | participants | |
| Number of Participants With Positive/Negative Neutralizing Antibody (NAb) and Anti-Drug Antibody (ADA) Tests | Interferon γ-1b | Week 28 (Follow-up) ADA = positive | 0 | participants | |
| Number of Participants With Positive/Negative Neutralizing Antibody (NAb) and Anti-Drug Antibody (ADA) Tests | Interferon γ-1b | Last On Study Assessment ADA = negative | 85 | participants | |
| Number of Participants With Positive/Negative Neutralizing Antibody (NAb) and Anti-Drug Antibody (ADA) Tests | Interferon γ-1b | Last On Study Assessment ADA = positive | 0 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02593773/results